Integrating radioembolization ( 90Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report

Andrew Kennedy; Douglas Coldwell; Bruno Sangro; Harpreet Wasan; Riad Salem

doi:10.1097/COC.0b013e3181ec60b8

Integrating radioembolization ( ⁹⁰Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report

Andrew Kennedy^*, Douglas Coldwell, Bruno Sangro, Harpreet Wasan, Riad Salem

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.

Original language	English (US)
Pages (from-to)	81-90
Number of pages	10
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	35
Issue number	1
DOIs	https://doi.org/10.1097/COC.0b013e3181ec60b8
State	Published - Feb 2012

Keywords

SIRT
Yttrium-90
chemoradiation
hepatic
metastases

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/COC.0b013e3181ec60b8

Cite this

@article{31aa7ae0bfe54497b422d12b9cf7c6d3,

title = "Integrating radioembolization ( 90Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report",

abstract = "Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.",

keywords = "SIRT, Yttrium-90, chemoradiation, hepatic, metastases",

author = "Andrew Kennedy and Douglas Coldwell and Bruno Sangro and Harpreet Wasan and Riad Salem",

year = "2012",

month = feb,

doi = "10.1097/COC.0b013e3181ec60b8",

language = "English (US)",

volume = "35",

pages = "81--90",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

Integrating radioembolization ( ⁹⁰Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report. / Kennedy, Andrew; Coldwell, Douglas; Sangro, Bruno et al.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 1, 02.2012, p. 81-90.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Integrating radioembolization ( 90Y Microspheres) into current treatment options for liver tumors

T2 - Introduction to the international working group report

AU - Kennedy, Andrew

AU - Coldwell, Douglas

AU - Sangro, Bruno

AU - Wasan, Harpreet

AU - Salem, Riad

PY - 2012/2

Y1 - 2012/2

N2 - Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.

AB - Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.

KW - SIRT

KW - Yttrium-90

KW - chemoradiation

KW - hepatic

KW - metastases

UR - http://www.scopus.com/inward/record.url?scp=84856304395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856304395&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181ec60b8

DO - 10.1097/COC.0b013e3181ec60b8

M3 - Article

C2 - 20938320

AN - SCOPUS:84856304395

SN - 0277-3732

VL - 35

SP - 81

EP - 90

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 1

ER -